Appropriate Use Criteria for Coronary Revascularization in Patients with Acute Coronary Syndromes: Members of the Writing Group, Rating Panel, Indication Reviewers, and AUC Task Force—Relationships with Industry and Other Entities (Comprehensive) Note: A standard exemption to the ACC RWI policy is extended to Appropriate Use Criteria writing groups, they do not make recommendations but rather prepare background materials and typical clinical scenarios/indications that are rated independently by a separate panel of experts. Institutional, Ownership/ or Other Speaker’s Partnership/ Personal Financial Expert Participant Employment Consultant Bureau Principal Research Benefit Witness Writing Group Manesh R. Patel Duke University Bayer None None AHQR None None • (Chair) Health System, Healthcare† Duke Clinical Astra Zeneca Genzyme • • Research General Medscape - – • Institute Cardiology — theheart.org Associate Merck (Co-PI)† • Professor of Duke CME Jansen • • Medicine, Director Johnson & • Interventional Johnson – Cardiology Arrhythmias and & Clinical Labs EP (Co-PI)† Maquet • Nat’l Heart • Lung & Blood Inst - Noninvasive Imaging (Co-PI)† Trial (Co-PI) • Nat’l Trial Lung & Blood Inst - Noninvasive Imaging * (PI) John H. Calhoon University of None None None None None None Texas Health Science Center at San Antonio Department of Cardiothoracic Surgery, Heart and Vascular Institute Director and —Professor Chair, Presidents Council Chair for Excellence in Surgery Gregory J. Baylor Scott & Member - FDA None None None Baylor Scott None • • Dehmer White - Temple Circulatory & White Memorial,Texas System Devices Health† A&M Health Panel of the Science Center Medical Devices College of Advisory Medicine, Past President • Central Texas - Society for Division Cardiovascular Angiography & Professor of Interventions* Medicine, Medical Director,
Appropriate Use Criteria for Coronary Revascularization in Patients with Acute Coronary Syndromes: Members of the Writing Group, Rating Panel, Indication Reviewers, and AUC Task Force—Relationships with Industry and Other Entities (Comprehensive) Note: A standard exemption to the ACC RWI policy is extended to Appropriate Use Criteria writing groups, they do not make recommendations but rather prepare background materials and typical clinical scenarios/indications that are rated independently by a separate panel of experts. Participant Employment Consultant Speaker’s Bureau Ownership/ Partnership/ Principal Personal Research Institutional, or Other Financial Benefit Expert Witness Writing Group Manesh R. Patel (Chair) Duke University Health System, Duke Clinical Research Institute Professor of Medicine, Director Interventional Cardiology and Labs Bayer Healthcare† • Genzyme • Medscape - theheart.org • Merck • Duke CME None None • AHQR • Astra Zeneca – General Cardiology (Co-PI)† • Jansen • Johnson & Johnson – Arrhythmias & Clinical EP (Co-PI)† • Maquet • Nat’l Heart Lung & Blood Inst - Noninvasive Imaging (Co-PI)† • (Co-PI) Nat’l Lung & Blood Inst - Noninvasive Imaging (PI) * None None John H. Calhoon University of Texas Health Science Center at San Antonio Department of Cardiothoracic Surgery, Heart and Vascular Institute Director —Professor and Chair, Presidents Council Chair for Excellence in Surgery None None None None None None Gregory J. Dehmer Baylor Scott & White - Temple Memorial,Texas A&M Health Science Center College of Medicine, Central Texas Division Professor of Medicine, Medical Director, • Member - FDA Circulatory System Devices Panel of the Medical Devices Advisory • Past President - Society for Cardiovascular Angiography & Interventions* None None None • Baylor Scott & White Health† None — Associate Trial Trial